Sign up to save your podcasts
Or
Share JAMA Oncology : Durvalumab With or Without Tremelimumab vs Standard Chemotherapy for Metastatic NSCLC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
JAMA Oncology : Durvalumab With or Without Tremelimumab vs Standard Chemotherapy for Metastatic NSCLC
Interview with Naiyer A. Rizvi, MD, author of Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
View all episodes
By The JAMA Network
4.9
1212 ratings
Interview with Naiyer A. Rizvi, MD, author of Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
More shows like JAMA Network
View all
JAMA Editors' Summary
137 Listeners
NEJM This Week
320 Listeners
AFP: American Family Physician Podcast
700 Listeners
JAMA Clinical Reviews
497 Listeners
Medicine and Science from The BMJ
37 Listeners
Diabetes Core Update
101 Listeners
Mayo Clinic Talks
288 Listeners
The Curbsiders Internal Medicine Podcast
3,342 Listeners
JAMA Pediatrics Editors' Summary
38 Listeners
JAMA Neurology Author Interviews
13 Listeners
JAMA Dermatology Author Interviews
16 Listeners
JAMA Internal Medicine Author Interviews
18 Listeners
JAMA Otolaryngology–Head & Neck Surgery Author Interviews
6 Listeners
Core IM | Internal Medicine Podcast
1,153 Listeners
JAMAevidence The Rational Clinical Examination
30 Listeners
Annals On Call Podcast
194 Listeners
JAMA Medical News
86 Listeners
The Clinical Problem Solvers
513 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
365 Listeners
Cardionerds: A Cardiology Podcast
432 Listeners
JAMAevidence JAMA Guide to Statistics and Methods
19 Listeners
The Curious Clinicians
370 Listeners
NEJM AI Grand Rounds
58 Listeners